The Effect of the COVID-19 Pandemic on Frailty in Liver Transplant Candidates
Study Details
Study Description
Brief Summary
Frailty is associated with higher rates of morbidity, mortality, and failure to rescue after major surgical procedures [1]. Sarcopenia is degenerative loss of skeletal muscle mass and strength. It is a key component of physical frailty and is associated with poorer post-surgical outcomes due to decreased patient strength and vitality.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This study seeks to examine whether the SARS-CoV-2 (COVID-19) pandemic, an ongoing global health crisis that was declared a national emergency by the US Federal Government on March 13, 2020, has exacerbated both frailty and sarcopenia in a population of liver transplant candidates.
Study Design
Outcome Measures
Primary Outcome Measures
- To determine the impact of the COVID-19 pandemic on the prevalence and incidence of sarcopenia [2 years]
To determine the impact of the COVID-19 pandemic on the prevalence and incidence of sarcopenia and frailty in patients undergoing liver transplant evaluation at Methodist Dallas Medical Center (MDMC).
Secondary Outcome Measures
- Changes in sarcopenia [1 yr]
Changes in number, type, and severity of comorbidities between pre- and during/post-pandemic
Eligibility Criteria
Criteria
Inclusion Criteria:
- Age 18 years and older Underwent pre-transplant frailty assessment (PFA) at MDMC
Exclusion Criteria:
- Not a patient at Liver Institute at Methodist Dallas
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Methodist Dallas Medical Center | Dallas | Texas | United States | 75203 |
Sponsors and Collaborators
- Methodist Health System
Investigators
- Principal Investigator: Parvez Mantry, MD, Methodist Health System
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 012.HEP.2022.D